The DESTINY-Lung01 phase II trial evaluated the efficacy of T-Dxd in two cohorts of NSCLC patients; cohort 1 contained patients with HER2 overexpression (i.e., IHC2+ or IHC3+), while cohort 2 contained patients with HER2 mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.